Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Dr. Santiago Ferro has been appointed as Chief Medical Officer
  • Dr. Ferro is a world-renowned physician with over 20 years of experience in the pharmaceuticals, biologicals and biotech industries
  • As VP of Clinical Affairs at Fio Corporation, he led the research and implementations of the Fionet system in Africa and Latin America
  • Core One is a biotechnology research and technology life sciences company
  • Core One Labs Inc. (COOL) opened trading at C$0.65 per share

Core One Labs (COOL) has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. as Chief Medical Officer.

Dr. Ferro will lead Core One Labs through clinical trials and commercialization of its psychedelic products.

Dr. Ferro is a graduate of Javeriana University Medical School in his native Bogotá, Colombia, where he specialized in Internal Medicine. Dr. Ferro received his sub-specialty training in Infectious Diseases at the University of Toronto. Following completion of his medical and specialty training, Dr. Ferro returned to Bogotá and established a private practice in both Internal Medicine and Infectious Diseases, while at the same time held academic positions at different teaching hospitals.

Dr. Ferro is a world-renowned physician with over 20 years of experience in the pharmaceuticals, biologicals and biotech industries. Throughout his career, Dr. Ferro has held many prestigious senior research and development management positions.

Dr. Ferro’s list of appointments includes Chief of Internal Medicine at Central Military Hospital in Bogotá, President of the Colombian Infectious Disease Society, Clinical Team Leader for new vaccines at Sanofi Pasteur in Toronto, Infectious Disease Expert at Novartis Pharmaceuticals in New Jersey and Medical Director at PATH’s Malaria Vaccine Initiative in Bethesda, Maryland.

Dr. Ferro was also VP of Clinical Affairs at Fio Corporation, where he led the clinical research and field implementations of the Fionet system in multiple countries in Africa and Latin America. Dr. Ferro also has an esteemed reputation in his fields of study, and has presented in multiple international scientific conferences, and has over twenty-five scientific publications in peer-reviewed journals and medical textbooks.

“I would like to welcome Dr. Ferro to the Core One team. Dr. Ferro’s breadth of experience in leading teams through product development, clinical and regulatory environments with major pharmaceutical companies, such as Sanofi Pasteur, Novartis and Glaxo Smith Klein are an invaluable asset to our team. We look forward to his leadership as we work towards the commercialization of psychedelic medicines,” stated Joel Shacker CEO of Core One Labs.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy. 

Core One Labs Inc. (COOL) opened trading at C$0.65 per share.

More From The Market Herald
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais

" Theratechnologies (TSX:TH) confirms effectiveness of PDCs against vasculogenic mimicry

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" MediPharm Labs (TSX:LABS) appoints new CEO

 MediPharm Labs (LABS) is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15,

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.